PPV/PET MF indicates post-polycythemic/post-ET MF; RUX, ruxolitinib; PBO, placebo; TSS, total symptom score; IWG-MRT, International Working Group for Myeloproliferative Neoplasms Research and Treatment; AE, adverse event; DLT, dose-limiting toxicity; ALT, alanine aminotransferase; AST, aspartate amino transferase; MTD, maximum tolerated dose; EORTC, European Organization for Research and Treatment of Cancer; and Fact-Lym, Functional Assessment of Cancer Therapy-Lymphoma.

*Several studies use different measurements for symptoms and therefore it is not possible to compare symptomatic improvements directly.